The Triggle effect

Abstract

Dr. David Triggle is considered a pioneer in the area of ion channel pharmacology. Over the course of his career, he made a number of particularly important contributions to our understanding of dihydropyridine interactions with L-type calcium channels. He also contributed his highly sought after expertise towards the drug discovery platform of the Canadian biopharmaceutical company, NeuroMed Pharmaceuticals (subsequently Zalicus). Here we briefly highlight his contributions to the field of calcium channel pharmacology, and then provide examples of his impact on NeuroMed.

Keywords: Calcium channels; Dihydropyridines; NeuroMed; Piperazines; Zalicus.